---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005499"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:26:28.703422+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics registers up to $110M in at-the-market stock offering

## Summary
- Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.
- Sales would be made under existing Sales Agreement dated July 1, 2025; no sales have occurred to date.
- Legal opinion from Goodwin Procter LLP filed as Exhibit 5.1.
- Offering is for general corporate purposes; no specific use of proceeds disclosed.

## SEC filing metadata
- accession: 0001193125-26-005499
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526005499/0001193125-26-005499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526005499/rapp-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005499
- JSON: https://secwatch.observer/filing/0001193125-26-005499.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005499.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.